Get started
Author

Karine Litherland

Observed name: K. Litherland
ORCID: 0009-0000-8243-0482
Observed ORCID: 0009-0000-8243-0482
OpenAlex ID: A5066564262
Biodistribution and Metabolism Studies of Lipid Nanoparticle–Formulated Internally [3H]-Labeled siRNA in Mice
2014 · Jesper Christensen, Karine Litherland, et al. · Drug Metabolism and Disposition · 63
Metabolism Studies of Unformulated Internally [3H]-Labeled Short Interfering RNAs in Mice
2013 · Jesper Christensen, Karine Litherland, et al. · Drug Metabolism and Disposition · 54
Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation
2014 · Nenad Manevski, Piet Swart, et al. · Drug Metabolism and Disposition · 52
Aldehyde Oxidase Activity in Fresh Human Skin
2014 · Nenad Manevski, Kamal Kumar Balavenkatraman, et al. · Drug Metabolism and Disposition · 30
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma
2021 · Stephan Braun, Paul McSheehy, et al. · Expert Opinion on Investigational Drugs · 20
Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
2021 · Christopher M. Rubino, Mark Polak, et al. · The Pediatric Infectious Disease Journal · 15
Whole-body scanning PCR; a highly sensitive method to study the biodistribution of mRNAs, noncoding RNAs and therapeutic oligonucleotides
2013 · Julien A. Boos, David W. Kirk, et al. · Nucleic Acids Research · 15
PDF
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
2024 · Elisa Zanini, Nicole Forster-Gross, et al. · Frontiers in Oncology · 10
PDF
Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia
2023 · Mark M. Hahn, Cheryl A. Triplett, et al. · Antibiotics · 6
PDF
Abstract 5645: BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity
2022 · Heidi A. Lane, Felix Bachmann, et al. · Cancer Research · 5
Design of A Metabolically Stable Tritium‐Tracer of the PI 3Kδ‐Inhibitor CDZ 173 (Leniolisib) as a Tool to Study Liver Metabolites
2018 · Carsten Bauer, Tong Luu, et al. · Helvetica Chimica Acta · 5
ADME studies of [5‐3H]‐2′‐O‐methyluridine nucleoside in mice: a building block in si RNA therapeutics
2016 · Frederic Lozac'h, Jesper Christensen, et al. · Pharmacology Research & Perspectives · 5
PDF
Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
2021 · Christopher M. Rubino, Anthony P. Cammarata, et al. · Antimicrobial Agents and Chemotherapy · 4
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma
2024 · Matthias Holdhoff, Xiaobu Ye, et al. · Neuro-Oncology Advances · 3
382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)
2020 · C. Tiu, A. Tzankov, et al. · Annals of Oncology · 3
PDF
42P BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity
2022 · H.A. Lane, E. Zanini, et al. · Annals of Oncology · 2
The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.
2021 · Crescens Diane Tiu, Sarah Derby, et al. · Journal of Clinical Oncology · 2
How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation
2026 · Borje Darpo, Georg Ferber, et al. · The Journal of Clinical Pharmacology · 1
Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults
2026 · Keith A. Rodvold, Mark H. Gotfried, et al. · Antimicrobial Agents and Chemotherapy · 1
Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques
2025 · Mark M. Hahn, Michael S. Anderson, et al. · Antimicrobial Agents and Chemotherapy · 1
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials
2025 · Thomas L Holland, Andrew F Shorr, et al. · Journal of Antimicrobial Chemotherapy · 1
2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
2023 · Sujata M Bhavnani, Jeffrey P Hammel, et al. · Open Forum Infectious Diseases · 1
PDF
Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection
2023 · Charlotte Cumper, Claire Richards, et al. · Journal of Medical Microbiology · 1
No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies
2026 · Borje Darpo, Hongqi Xue, et al. · Journal of Antimicrobial Chemotherapy
PDF
Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment
2026 · Carlos Fernando de Oliveira, Kathryn Lowe, et al. · Antimicrobial Agents and Chemotherapy
Works count: 29
Citation count: 300
H-index: 8
I10-index: 8
Year
Topic
Type